Abstract 3827
Background
Cemiplimab (cemiplimab-rwlc in the US), a human monoclonal anti–PD-1 antibody, has shown substantial antitumour activity in pts with advanced malignancies and is FDA-approved for pts with advanced (metastatic or locally advanced) cutaneous squamous cell carcinoma (CSCC). We sought to compare weight-based and fixed dosing regimens of cemiplimab in pts with advanced malignancies.
Methods
This PK analysis included 505 pts with advanced tumours, including 135 pts with advanced CSCC, from phase I and phase II studies of cemiplimab (NCT02383212 and NCT02760498, respectively). Pts received either weight-based doses of cemiplimab (1, 3, 10 mg/kg every 2 weeks [Q2W] and 3 mg/kg every 3 weeks [Q3W]) or a fixed dose regimen (200 mg Q2W). This analysis pooled data from 10,935 PK samples including 2,023 samples from pts with advanced CSCC, to predict the Q3W fixed dose regiment with equivalent cemiplimab exposure as the recommended Phase II dose (3 mg/kg Q2W) using a 2compartment population PK (PopPK) model incorporating covariates that improved goodness-of-fit statistics. The selected fixed dose regimen was confirmed by PK data of the regimen in pts with advanced CSCC from the phase II trial.
Results
In the phase I study, dose-proportional kinetics were observed over the 1 to 10 mg/kg Q2W dose range. The 350 mg Q3W fixed dose regimen was selected based on PopPK model simulations as it provided similar cemiplimab exposure to 3 mg/kg Q2W at steady state (ss) over a 6-week (6wk) treatment period (e.g. mean AUC6wk, ss [coefficient of variation (CV)]: 3,800 [37.2%] and 3,710 [35.9%] mg*day/mL for 350 mg Q3W and 3 mg/kg Q2W, respectively). The observed exposures in patients with advanced CSCC in the phase II trial receiving 350 mg Q3W cemiplimab were comparable to the simulated exposures. In addition, the observed exposures at ss were similar between 3 mg/kg Q2W and 350 mg Q3W.
Conclusions
The results from PopPK simulations support the use of a 350 mg Q3W fixed dose regimen, with similar cemiplimab exposure to a weight-based 3 mg/kg Q2W regimen, in pts with advanced malignancies.
Clinical trial identification
NCT02383212 and NCT02760498.
Editorial acknowledgement
Bu Reinen of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc., and Sanofi.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc., and Sanofi.
Funding
Regeneron Pharmaceuticals, Inc., and Sanofi.
Disclosure
M.R. Migden: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Regeneron Pharmaceuticals, Inc.; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly; Honoraria (self), Travel / Accommodation / Expenses: Sun Pharma. A. Paccaly: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. K.P. Papadopoulos: Research grant / Funding (institution): Regeneron Pharmaceuticals, Inc.; Research grant / Funding (institution): Merck; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Merck KGaA; Research grant / Funding (institution): Mabspace Biosciences. F. Yang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. J.D. Davis: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. R. Rippley: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. I. Lowy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. M.G. Fury: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. E. Stankevich: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. D. Rischin: Research grant / Funding (institution), Non-remunerated activity/ies: Regeneron Pharmaceuticals, Inc.; Research grant / Funding (institution), Non-remunerated activity/ies: GSK; Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Merck; Research grant / Funding (institution), Non-remunerated activity/ies: Bristol-Myers Squibb; Research grant / Funding (institution): Roche.
Resources from the same session
3361 - Providing a nurse-led telephone intervention for patients treated with oral anticancer medication: symptom management and adherence monitoring
Presenter: Etienne Minvielle
Session: Poster Display session 3
Resources:
Abstract
3937 - Chronological evaluation of health-related quality of life and physical symptoms in postoperative pancreatic cancer patients up to 12 months
Presenter: Naoko Sato
Session: Poster Display session 3
Resources:
Abstract
5620 - Understanding the patients’ Experiences of Radiation Therapy: A Qualitative Study on Prostate Cancer Patients
Presenter: Sakarias Johansson
Session: Poster Display session 3
Resources:
Abstract
1792 - Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy
Presenter: Aydan Uravylioglu
Session: Poster Display session 3
Resources:
Abstract
2169 - The Meaning of Responsibility – a Secondary Analysis of Patients and Caregivers Calls to an Oncology Emergency Telephone
Presenter: Heidi Jacobsen
Session: Poster Display session 3
Resources:
Abstract
4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Elif Dil
Session: Poster Display session 3
Resources:
Abstract
1981 - Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
Presenter: CESCA PUIGMARTI
Session: Poster Display session 3
Resources:
Abstract
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.
Presenter: Marina Bosch - Damas
Session: Poster Display session 3
Resources:
Abstract
5112 - Symptomatic and toxicity management of cancer patients using a telephone support model led by the oncology nurse
Presenter: Gemma Simó
Session: Poster Display session 3
Resources:
Abstract
1365 - Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Presenter: Xiaole HE
Session: Poster Display session 3
Resources:
Abstract